

## POLICY

### PATIENT MEDICATION CONTRACTS

3019

#### Chronic Pain Management

The use of narcotics in addition to tramadol (those medications for treatment of pain in schedule CII – CIV) will be used as indicated for acute trauma and temporary painful conditions for an appropriate period of time deemed medically necessary by the provider.

Prescriptions and refills will be authorized only by the provider.

All patients who use pain medications for chronic conditions will be required to sign and adhere to a pain management contract. This contract is also used for controlled substances as described below. In addition to the contract, chronic pain patients are also required to sign an MRN (Material Risk Notice) related to drug therapy and patient specific goals

A review of charts of patients needing chronic pain management and narcotics will be conducted according to scheduled indicators per Chief Medical Officer Chart review and QI process.

#### Stimulants:

All patients 18 and older prescribed stimulants (schedule II) used to treat ADHD (attention deficit hyperactivity disorder) will be required to sign and adhere to a controlled substance contract related to this medication. In addition, patients will sign and receive an MRN (material risk notice) related to medication and goals of therapy.


A review of charts of patients prescribed stimulants 18 and older will be conducted according to scheduled indicators as part of Chief Medical Officer Chart Reviews and QI process.

#### Benzodiazepines:

The use of benzodiazepines will be used as indicated for short term and acute patient situations for an appropriate period of time deemed necessary by provider.

All patients who use benzodiazepines for chronic, long term use (longer than 3 months) will be required to sign and adhere to a controlled substance contract. In addition, patients will sign and receive an MRN (material risk notice) related to medication therapy and goals. Any patient that is also prescribed narcotics will automatically be reviewed by the controlled substance committee.

A review of charts of patients prescribed benzodiazepines long term will be conducted according to scheduled indicators as a part of the Chief Medical Officer Chart Reviews and QI process.

  
\_\_\_\_\_  
CHIEF EXECUTIVE OFFICER

Date 1-13-2020

  
\_\_\_\_\_  
CHAIR, BOARD OF DIRECTORS

Date: 1-13-2020

Date first adopted	11/01/2007
Date Revised/QI Board approval	04/29/2015, 12/23/2019
New date adopted/Board of Directors approval	05/11/2015, 01/13/2020